COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449936 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Macular Edema
DME
Diabetic Macular Edema (DME)

Interventions

DRUG: EYP-1901
DRUG: Aflibercept (2.0 mg)

Sponsor

EyePoint Pharmaceuticals, Inc.